Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis

Shaihana Abdulrahman Almatrrouk; Anthony Oliver; Lynne Hampson; Ian N Hampson

doi:10.2217/fvl.14.50

Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis

Shaihana Abdulrahman Almatrrouk, Anthony Oliver, Lynne Hampson, Ian N Hampson

Research output: Contribution to journal › Article › peer-review

Abstract

Worldwide, at least 170 million people are infected with hepatitis C virus (HCV), which is associated with hepatocellular carcinoma (HCC). With the recent success of Sofosbuvir (and other agents) antiviral therapy may be used as a future early-stage HCC treatment; however, in the short term, a cost-effective solution is needed to treat patients with viral-associated HCC. Here, we emphasize the potential of targeting gap junction intercellular communication (GJIC) as a therapeutic approach for HCC as HCV perturbs GJIC, which is linked to cellular transformation. We review the ROCK inhibitor Y-27632 and structurally related compounds that may inhibit the carcinogenic properties of HCV.

Original language	English
Pages (from-to)	679-692
Number of pages	13
Journal	Future Virology
Volume	9
Issue number	7
DOIs	https://doi.org/10.2217/fvl.14.50
Publication status	Published - Jul 2014

Keywords

HCV, Rho KInase Inhibitors, Gap junctions, Gap Junction Intracellular Communication, GJIC Hepatocellular Carcinoma, Liver cancer, Y27632

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fvl.14.50

Cite this

@article{fdb487a4022b46598fb35c42696f849f,

title = "Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis",

abstract = "Worldwide, at least 170 million people are infected with hepatitis C virus (HCV), which is associated with hepatocellular carcinoma (HCC). With the recent success of Sofosbuvir (and other agents) antiviral therapy may be used as a future early-stage HCC treatment; however, in the short term, a cost-effective solution is needed to treat patients with viral-associated HCC. Here, we emphasize the potential of targeting gap junction intercellular communication (GJIC) as a therapeutic approach for HCC as HCV perturbs GJIC, which is linked to cellular transformation. We review the ROCK inhibitor Y-27632 and structurally related compounds that may inhibit the carcinogenic properties of HCV.",

keywords = "HCV, Rho KInase Inhibitors, Gap junctions, Gap Junction Intracellular Communication, GJIC Hepatocellular Carcinoma, Liver cancer, Y27632",

author = "Almatrrouk, {Shaihana Abdulrahman} and Anthony Oliver and Lynne Hampson and Hampson, {Ian N}",

year = "2014",

month = jul,

doi = "10.2217/fvl.14.50",

language = "English",

volume = "9",

pages = "679--692",

journal = "Future Virology",

issn = "1746-0794",

publisher = "Future Medicine ",

number = "7",

}

TY - JOUR

T1 - Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis

AU - Almatrrouk, Shaihana Abdulrahman

AU - Oliver, Anthony

AU - Hampson, Lynne

AU - Hampson, Ian N

PY - 2014/7

Y1 - 2014/7

N2 - Worldwide, at least 170 million people are infected with hepatitis C virus (HCV), which is associated with hepatocellular carcinoma (HCC). With the recent success of Sofosbuvir (and other agents) antiviral therapy may be used as a future early-stage HCC treatment; however, in the short term, a cost-effective solution is needed to treat patients with viral-associated HCC. Here, we emphasize the potential of targeting gap junction intercellular communication (GJIC) as a therapeutic approach for HCC as HCV perturbs GJIC, which is linked to cellular transformation. We review the ROCK inhibitor Y-27632 and structurally related compounds that may inhibit the carcinogenic properties of HCV.

AB - Worldwide, at least 170 million people are infected with hepatitis C virus (HCV), which is associated with hepatocellular carcinoma (HCC). With the recent success of Sofosbuvir (and other agents) antiviral therapy may be used as a future early-stage HCC treatment; however, in the short term, a cost-effective solution is needed to treat patients with viral-associated HCC. Here, we emphasize the potential of targeting gap junction intercellular communication (GJIC) as a therapeutic approach for HCC as HCV perturbs GJIC, which is linked to cellular transformation. We review the ROCK inhibitor Y-27632 and structurally related compounds that may inhibit the carcinogenic properties of HCV.

KW - HCV, Rho KInase Inhibitors, Gap junctions, Gap Junction Intracellular Communication, GJIC Hepatocellular Carcinoma, Liver cancer, Y27632

U2 - 10.2217/fvl.14.50

DO - 10.2217/fvl.14.50

M3 - Article

SN - 1746-0794

VL - 9

SP - 679

EP - 692

JO - Future Virology

JF - Future Virology

IS - 7

ER -

Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this